2
项与 瑞舒伐他汀/ω-3酸乙酯 相关的临床试验NMDA Enhancement Combined With Omega-3 Fatty Acids for the Treatment of Early Dementia
In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a 24-week randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: [1] DAOIB + omega-3; [2] DAOIB + placebo. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.
A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007 in Healthy Male Volunteers
The purpose of this study is to evaluate the pharmacokinetics of omega-3 between rosuvastatin and omega-3 coadministration and HCP1007 in healthy male volunteers.
100 项与 瑞舒伐他汀/ω-3酸乙酯 相关的临床结果
100 项与 瑞舒伐他汀/ω-3酸乙酯 相关的转化医学
100 项与 瑞舒伐他汀/ω-3酸乙酯 相关的专利(医药)
100 项与 瑞舒伐他汀/ω-3酸乙酯 相关的药物交易